AIxCrypto Partners with BitMart to Launch Co-Branded Virtual Prepaid Cards for Web3 Users
- Partnered with BitMart to launch co-branded virtual prepaid cards, extending Web3 payments via a licensed operator.
- BitMart handles issuance and compliance; AIxC supplies community, marketing, product innovation, minimizing regulatory exposure.
- Launched Season 2, reports 1.64M wallets and 7,200 teams; prioritizes AI automation, developer tooling, institutional outreach.
Intro: AIxCrypto moves to bridge digital ecosystems with regulated payments
AIxCrypto Inc. (AIxC) announces a strategic partnership with crypto exchange BitMart to launch a co-branded virtual prepaid card program for eligible users in the AIxC ecosystem. The tie-up positions AIxC to extend Web3 utility into everyday payment channels while keeping regulated financial operations with a licensed partner. Company leadership frames the initiative as a practical step toward real-world use cases for blockchain-native communities.
BitMart to operate issuance, AIxC to drive demand
Under the arrangement, BitMart acts as the exclusive operator, handling card issuance, user onboarding, compliance oversight, customer support and all payment infrastructure subject to regional and regulatory requirements. AIxC supplies community reach, brand participation and marketing support, creating a clear operational split that leaves regulated payments and custody to licensed entities. The structure aims to reduce regulatory exposure for AIxC while enabling a scalable payments experience for its user base.
Strategic aim: real-world utility without becoming a regulated financial provider
AIxC frames the program as part of a broader push for compliant payment rails that convert on-chain engagement into off-chain purchasing power. By outsourcing regulated functions to BitMart, AIxC concentrates on product innovation, community growth and integration of AI-driven features across its ecosystem. The company signals this model as a template for future collaborations where it supplies developer tooling, user experience and distribution while licensed partners handle financial regulation and settlement.
Seasonal gaming, platform growth and features
Separately, AIxC completes Season 1 of AIxC Hub’s competitive S1 Arena and launches Season 2, transforming the Hub into a Web2-to-Web3 gateway powered by AI Agent infrastructure and integrated with the EAI‑RWA ecosystem. Season-based simulations, leaderboards and per-season settlements now evolve into new features such as Tenki Stargaze and Fortune Collection. AIxC reports more than 1.64 million registered wallet addresses and over 7,200 registered teams.
Institutional outreach and developer engagement
AIxC co-hosts a panel at ConsensusHK titled “Beyond Scaling: AIxC and the Era of Autonomous DeFi,” reinforcing engagement with institutions and developers. The company states its roadmap prioritizes AI-driven automation, developer tooling and institutional outreach, and it plans to convert conference momentum into partnerships, platform integrations and measurable user onboarding over coming quarters.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…